3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
3
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Esophageal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
14
Nivolumab
9
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
atezolizumab
3
Ipilimumab
3
Drug Therapy
3
Cyclophosphamide
3
epacadostat
2
entrectinib
2
durvalumab
2
X-Rays
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Methods
2
Interleukin-2
2
Injections
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
Biopsy
2
zimberelimab
1
vocimagene amiretrorepvec
1
varlilumab
1
utomilumab
1
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
zimberelimab
×
Lymphoid
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled